| Name | Title | Contact Details |
|---|---|---|
David Hoffman |
Chief Compliance Officer | Profile |
Sean Flynn |
Vice President, General Counsel and Corporate Secretary | Profile |
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina`s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
MBX Biosciences is a preclinical-stage biotechnology company using validated molecular targets to create medicines for rare endocrine diseases where current therapies are inadequate.
Relay has developed a proprietary software solution for stakeholders of the biopharmaceutical technology licensing and development process.
Tactiva is an immuno-oncology company based in Buffalo, New York, utilizing an innovative, dual T cell receptor (TCR) approach to adoptive T cell therapy.
United Review Services is a Piscataway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.